Clinical trials: Moderate to Severe Chronic Pain
Pain, Osteoarthritis
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a…
- Conditions
- Pain, Osteoarthritis, Low Back Pain
- Trial name
- NCT00487435
- Testing
- Tapentadol (CG5503) Extended Release (ER)
- Where
- 148 sites in United States, Australia and 2 more
- Volunteers
- 1,166 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain, Osteoarthritis of the Knee
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to…
- Trial name
- NCT00531427
- Testing
- Buprenorphine
- Where
- 87 sites in United States
- Volunteers
- 567 people
- Sponsor
- Purdue Pharma LP
Chronic Pain, Diabetic Neuropathies
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing…
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Trial name
- NCT01939366
- Testing
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg
- Where
- 82 sites in United States, Austria and 6 more
- Volunteers
- 699 people
- Sponsor
- Tris Pharma, Inc.
Low Back Pain
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
The primary objective of this study is to evaluate the efficacy of hydrocodone bitartrate extended-release tablets at doses of 30 to 90 mg every 12 hours compared with placebo in alleviating moderate to severe pain in patients…
- Trial name
- NCT01789970
- Testing
- Hydrocodone ER
- Where
- 87 sites in United States
- Volunteers
- 625 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain
Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
- Trial name
- NCT00412100
- Testing
- Oxycodone naloxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Chronic Pain
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
This Phase 3, multi-center study will evaluate the long-term safety and tolerability of hydrocodone bitartrate controlled release capsule (HC-CR) at daily doses of 40 mg or more in subjects with moderate to severe chronic pain.
- Trial name
- NCT01115569
- Testing
- Hydrocodone Bitartrate
- Where
- 50 sites in United States
- Volunteers
- 424 people
- Sponsor
- Zogenix, Inc.
Pain, Low Back Pain
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain
The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.
- Conditions
- Pain, Low Back Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT01298765
- Testing
- BEMA Buprenorphine
- Where
- 26 sites in United States
- Volunteers
- 302 people
- Sponsor
- BioDelivery Sciences International
Osteoarthritis, Pain
Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine
The primary objective of this equivalence study is to evaluate the efficacy of Norspan® patches versus Tramadol in subjects with chronic, moderate to severe osteoarthritis pain of the hip, knee and/or lumbar spine.
- Trial name
- NCT00426647
- Testing
- Buprenorphine, Tramadol
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- Norpharma A/S